H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Advaxis (NASDAQ: ADXS) today and set a price target of $3. The company’s shares closed yesterday at $1.44, close to its 52-week low of $1.40.
Ramakanth said:
“We maintain our Buy rating of ADXS and our 12-month price target of $3.00 per diluted share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple (6x 2026 sales estimate at 14% discount); and (2) price-earnings multiple (19x 2026 earnings estimate at 14% discount). (1) clinical; (2) financial; (3) regulatory; (4) commercial; and (5) intellectual property.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 8.4% and a 40.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
Currently, the analyst consensus on Advaxis is a Moderate Buy with an average price target of $2.50.
See today’s analyst top recommended stocks >>
Based on Advaxis’ latest earnings release for the quarter ending April 30, the company reported a quarterly GAAP net loss of $13.41 million. In comparison, last year the company had a GAAP net loss of $20.47 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins.
